Sign in
CompletedPhase 3

Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP

Key facts

Who runs it
Centers for Disease Control and Prevention
Where
Peru2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
192 people enrolled
Started
4 Nov 2022
Ended
4 May 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • FLUAD Quadrivalent
  • FluQuadri
Record updated
19 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • ≥18 years old
  • Have participated in the healthcare personnel cohort study at Hospital Nacional Cayetano Heredia or Hospital Nacional Arzobispo Loayza during 2016-2021
  • Work at the facility full-time (≥30 hours per week)
  • Have routine, direct, hands-on or face-to-face contact with patients (≤1 meter) as part of a typical work shift, including, but not limited to, physicians, nurses, respiratory therapists, physical therapists, unit clerks, radiograph technicians, medical assistants, and transporters
  • Work at the facility for ≥1 year prior to enrollment and planning to continue working at the facility for one year after enrollment
  • Willing to receive influenza vaccination (adjuvanted or standard dose)
  • Women of childbearing age must complete the following criteria to be eligible:; Have a negative urine pregnancy test performed by the study staff ≤24 hours preceding receipt of the vaccine; Be willing to use a reliable form of contraception approved by the Investigator for ≤2 months after receiving the vaccine. If they are not currently using an approved contraceptive, study staff will provide access to contraceptives; Must not be breastfeeding

Who cannot take part

  • Have received a vaccine against influenza during the 2022 influenza season (season of clinical trial)
  • Received blood or blood products within 3 months of enrollment
  • Have a severe, life-threatening allergy to influenza vaccines, eggs, or influenza vaccine components
  • Have a history of Guillain-Barre Syndrome or other autoimmune diseases
  • Be pregnant, confirmed by rapid pregnancy test

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized, double-blinded trial will assess humoral immune responses to adjuvanted, egg-based quadrivalent influenza vaccines compared to standard dose, egg-based quadrivalent influenza vaccines among healthcare personnel (HCP). The trial will be conducted at two sites in Lima, Peru during 2022 and 2023.

The 2 groups in the trial

  • FLUAD QuadrivalentTreatment being tested

    Participants administered a single dose of adjuvanted egg-based quadrivalent influenza vaccine (FLUAD Quadrivalent by Seqirus, 15 µg of HA from each strain).

  • FluQuadriExisting treatment, for comparison

    Participants administered a single dose of standard dose egg-based quadrivalent influenza vaccine (FluQuadri by Sanofi-Pasteur, 15 µg of HA from each strain).

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Controlled Trial, Double Blind, Phase III, to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among Health Care Personnel (EDUCATE)
Publications
Record updated
19 May 2026